Obeticholic acid, a farnesoid X receptor (FXR) agonist structurally similar to chenodeoxycholic acid, has demonstrated positive effects in clinical trials for type 2 diabetes and NAFLD. The gene discussed is NR1H4; the disease is type 2 diabetes mellitus.